The impact of an etoposide shortage on patients with extensive-stage small cell lung cancer (ES-SCLC): Results of a natural experiment

被引：0
|
作者：
Browne, C. [1 ]
Ayoube, T. [2 ]
Samarasinghe, N. [3 ]
Hussaini, K. [4 ]
Warner, A. [5 ]
Black, M. [6 ]
Palma, D. A. [6 ]
Raphael, J. [6 ]
Kuruvilla, M. S. [6 ]
Blanchette, P. [6 ]
机构：
[1] Univ Western Ontario, Med Oncol, London, ON, Canada
[2] Univ Western Ontario, Sci, London, ON, Canada
[3] Univ British Columbia, Surg, Fac Med, Vancouver Gen Hosp, Vancouver, BC, Canada
[4] Oakville Trafalgar Mem Hosp, Dept Oncol, London, ON, Canada
[5] London Hlth Sci Ctr, Dept Radiat Oncol, London Reg Canc Program LRCP, London, ON, Canada
[6] London Hlth Sci Ctr, Dept Med Oncol, London Reg Canc Program LRCP, London, ON, Canada
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.1227
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1996P
引用
收藏
页码：S1065 / S1065
页数：1
相关论文
共 50 条
  • [21] Final results and subgroup analysis of ORIENTAL: A phase IIIB study of durvalumab plus platinum-etoposide in firstline treatment of Chinese patients with extensive-stage small-cell lung cancer (ES-SCLC)
    Cheng, Y.
    Wang, J.
    Yao, W.
    Yu, Y.
    Zang, A.
    Cao, L.
    Lv, D.
    Li, S.
    Meng, Z.
    Zhang, J.
    Guo, Q.
    Huang, D.
    Liu, A.
    Liu, J.
    Mao, W.
    Tang, K.
    Zhang, Y.
    Chen, E.
    Wang, Z.
    Zheng, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S1673 - S1673
  • [22] Ifinatamab Deruxtecan (I-DXd) in Extensive-Stage Small Cell Lung Cancer (ES-SCLC): Interim Analysis of Ideate-lung01
    Rudin, C. M.
    Ahn, M. -J.
    Johnson, M.
    Hann, C. L.
    Girard, N.
    Nishio, M.
    Cheng, Y.
    Hayashi, H.
    Kim, Y. Jung
    Navarro, A.
    Chen, Y.
    Sakai, T.
    Qian, M.
    Godard, J.
    Tang, M.
    Singh, J.
    Paz-Ares, L.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S15 - S16
  • [23] REAL-WORLD TREATMENT DURATION OF ATEZOLIZUMAB plus CARBOPLATIN plus ETOPOSIDE AMONG OLDER PATIENTS WITH EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC) AND THE IMPACT OF PERFORMANCE STATUS AND BRAIN METASTASES
    Albarmawi, Husam
    Robinson, Scott
    Dietz, Kevin
    Norris, Kris
    Paranthaman, Nindhana
    Ogale, Sarika
    Schwartz, Taylor
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A830 - A830
  • [24] Adoption and early clinical outcomes of atezolizumab (atezo) plus carboplatin and etoposide (CE) in patients with extensive-stage small cell lung cancer (ES-SCLC) in the real-world (RW) setting
    Tsui, D. C. C.
    Polito, L.
    Madhavan, S.
    Adler, L.
    Ogale, S.
    Camidge, D. R.
    ANNALS OF ONCOLOGY, 2021, 32 : S1164 - S1164
  • [25] Prognostic Factors in Extensive-Stage Small Cell Lung Cancer (SCLC)
    De Almeida, S. B.
    Vitorino, M.
    Goncalves, S.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S34 - S35
  • [26] Durvalumab (D) plus platinum-etoposide (EP) in 1L extensive-stage small-cell lung cancer (ES-SCLC): Exploratory analysis of SCLC molecular subtypes in CASPIAN
    Xie, Mingchao
    Chugh, Priti
    Broadhurst, Helen
    Lai, Zhongwu
    Whitston, David
    Paz-Ares, Luis
    Gay, Carl
    Byers, Lauren
    Rudin, Charles M.
    Stewart, Ross
    Barrett, J. Carl
    Shrestha, Yashaswi
    Panse, Jens
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 145 - 145
  • [27] Prognostic impact of leptin (LEP)-mediated meta-inflammation (MI) in patients (pts) receiving maintenance immunotherapy (IT) for extensive-stage small cell lung cancer (ES-SCLC)
    Vita, E.
    Stefani, A.
    Piro, G.
    Sparagna, I.
    Monaca, F.
    Di Salvatore, M.
    Ferrara, M. G.
    Barone, D.
    D'Argento, E.
    Carbone, C.
    Tortora, G.
    Bria, E.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1250 - S1250
  • [28] Durvalumab (D) plus platinum-etoposide (EP) in 1L extensive-stage small-cell lung cancer (ES-SCLC): Exploratory analysis of SCLC molecular subtypes in CASPIAN
    Xie, Mingchao
    Chugh, Priti
    Broadhurst, Helen
    Lai, Zhongwu
    Whitston, David
    Paz-Ares, Luis
    Gay, Carl
    Byers, Lauren
    Rudin, Charles M.
    Stewart, Ross
    Barrett, J. Carl
    Shrestha, Yashaswi
    CANCER RESEARCH, 2022, 82 (12)
  • [29] Trilaciclib (T) decreases myelosuppression in extensive-stage small cell lung cancer (ES-SCLC) patients receiving first-line chemotherapy plus atezolizumab
    Daniel, D.
    Kuchava, V.
    Bondarenko, I.
    Ivashchuk, O.
    Spigel, D.
    Dasgupta, A.
    Reddy, S.
    Melkadze, T.
    Jaal, J.
    Kudaba, I.
    Hart, L.
    Matitashvili, A.
    Koynov, K. D.
    Yang, Z.
    Wolfe, S. G.
    Malik, R.
    Morris, S. R.
    Antal, J. M.
    Goldschmidt, J.
    ANNALS OF ONCOLOGY, 2019, 30 : 713 - 713
  • [30] UPDATED PFS ANALYSIS OF TORIPALIMAB WITH ANLOTINIB AND CHEMOTHERAPY AS FIRST-LINE THERAPY IN PATIENTS WITH EXTENSIVE-STAGE SMALL-CELL LUNG CANCER (ES-SCLC)
    Luo, Hao
    Jian, Dan
    Feng, Yan
    Zhong, Li
    Chen, Qian
    Guan, Wei
    Zhang, Shiheng
    Luo, Jiamin
    Yang, Xueqin
    Gong, Kan
    Xiong, Yanli
    Li, Mengxia
    Xu, Mingfang
    Pu, Yu
    Zhao, Liang
    Qian, Chengyuan
    Dai, Nan
    Wang, Dong
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A490 - A490
12345